IP Library Granted Patent US 10,358,678
Granted Patent B2
US 10,358,678 · App. 15/437,147 · Granted Jul 23, 2019

Methods for identifying subjects with a genetic risk for developing IgA nephropathy

Inventors: Ali Gharavi (New York, NY); Krzysztof Kiryluk (New York, NY); Richard Lifton (North Haven, CT)
Assignees: The Trustees of Columbia University in the City of New York; Yale University
C12Q1/6883C12Q2600/112C12Q2600/136C12Q2600/156C12Q2600/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,358,678
App. No.
15/437,147
Granted
Jul 23, 2019
Kind
B2
Abstract

Seven protective alleles for IgA nephropathy have been discovered that can be identified by analyzing a DNA sample for seven respective SNPs. A method is provided for identifying and treating subjects at risk of developing IgA neuropathy based on a new seven-SNP genetic risk score. Also provided are screening methods to identify compounds that bind to and reduce the expression or biological activity of a either CFHR1 or CFHR3.

Claims (11)

1. A method, comprising

a) obtaining a DNA sample from a subject,

b) a analyzing the DNA sample to detect the presence of one or more SNPs indicating a respective protective allele, wherein the SNPs analyzed comprise rs6677604, rs3766404, rs9275596, rs9275224, rs2856717, rs9357155, rs2071543, rs1883414, rs3129269, rs2412971, or rs2412973, or a combination thereof and

c) identifying the subject as not having at least one protective allele; and

d) treating the subject identified as not having at least one protective allele for IgAN.

2. The method of claim 1 , further comprising calculating a genetic risk score comprising determining a weighted sum of the number the protective alleles in the DNA sample multiplied by the log of the odds ratio for each of the individual protective alleles.

3. The method of claim 1 , wherein the subject has blood or protein, or both in the urine.

4. The method of claim 1 , wherein treating the subject for IgAN comprises administering therapeutically effective amounts of one or more steroids.

5. The method of claim 1 , further comprising calculating a genetic risk score based on the presence of one or more of the protective alleles.

6. The method of claim 5 , further comprising analyzing an ethnicity of the subject, and wherein the odds ratio for each of the individual protected alleles is determined based on the ethnicity of the subject.

7. The method of claim 5 , wherein the risk score is based on the presence of one or more alleles selected from the group of rs9275596, rs9357155, rs1883414, rs2412971, and rs6677604.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 21, 2017
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043933/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: LIFTON, RICHARD
To: YALE UNIVERSITY
Reel/Frame 043346/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: GHARAVI, ALI; KIRYLUK, KRZYSZTOF
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 043613/0273 →
Continuity (4)
Division 14000328
Provisional Application 61444583 · Feb 18, 2011
Provisional Application 61444126 · Feb 17, 2011
Related Publication 20170226586A1 · Aug 10, 2017